Posted AT 6:15 PM EST on 27/10/09
Exploring the world of vaccine stocks
The swine flu may be dominating headlines because of its enormous public-health implications, but its vaccine also points to a profound change in the North American pharmaceutical industry: Big pharma has started to look at vaccines as a crucial new revenue stream. In the last month alone, there have been several large deals centred on vaccines: Johnson & Johnson paid $440-million (U.S.
The full text of this article has 978 words.
To continue reading this article, you will need to purchase this article.
This article is NOT available for licensing for re-use and redistribution.
Already have a member account? Login now
Pay-Per-View Offers To read the complete article, select one of the following options
Purchasing from globeandmail.com is quick and secure.
